npj Precision Oncology (Feb 2024)

Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations

  • Higinio Dopeso,
  • Andrea M. Gazzo,
  • Fatemeh Derakhshan,
  • David N. Brown,
  • Pier Selenica,
  • Sahar Jalali,
  • Arnaud Da Cruz Paula,
  • Antonio Marra,
  • Edaise M. da Silva,
  • Thais Basili,
  • Laxmi Gusain,
  • Lorraine Colon-Cartagena,
  • Shirin Issa Bhaloo,
  • Hunter Green,
  • Chad Vanderbilt,
  • Steffi Oesterreich,
  • Anne Grabenstetter,
  • M. Gabriela Kuba,
  • Dara Ross,
  • Dilip Giri,
  • Hannah Y. Wen,
  • Hong Zhang,
  • Edi Brogi,
  • Britta Weigelt,
  • Fresia Pareja,
  • Jorge S. Reis-Filho

DOI
https://doi.org/10.1038/s41698-024-00508-x
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 11

Abstract

Read online

Abstract CDH1 (E-cadherin) bi-allelic inactivation is the hallmark alteration of breast invasive lobular carcinoma (ILC), resulting in its discohesive phenotype. A subset of ILCs, however, lack CDH1 genetic/epigenetic inactivation, and their genetic underpinning is unknown. Through clinical targeted sequencing data reanalysis of 364 primary ILCs, we identified 25 ILCs lacking CDH1 bi-allelic genetic alterations. CDH1 promoter methylation was frequent (63%) in these cases. Targeted sequencing reanalysis revealed 3 ILCs harboring AXIN2 deleterious fusions (n = 2) or loss-of-function mutation (n = 1). Whole-genome sequencing of 3 cases lacking bi-allelic CDH1 genetic/epigenetic inactivation confirmed the AXIN2 mutation and no other cell-cell adhesion genetic alterations but revealed a new CTNND1 (p120) deleterious fusion. AXIN2 knock-out in MCF7 cells resulted in lobular-like features, including increased cellular migration and resistance to anoikis. Taken together, ILCs lacking CDH1 genetic/epigenetic alterations are driven by inactivating alterations in other cell adhesion genes (CTNND1 or AXIN2), endorsing a convergent phenotype in ILC.